Haemate P (Human Coagulation Factor Viii, Human Von Willebrand Factor)

Haemate P is indicated for the management of bleeding disorders that involve deficiency of factor VIII and von Willebrand factor.

• Treatment of acute bleeding episodes in patients with hemophilia A.
• Routine prophylaxis to prevent spontaneous bleeds in hemophilia A.
• Management of bleeding episodes in von Willebrand disease types 1, 2, and 3.
• Perioperative control of hemostasis for surgical or dental procedures in affected individuals.

Adverse reactions reported with Haemate P vary in frequency and severity.

Common

• Headache.
• Fever.
• Nausea or vomiting.
• Injection site reactions such as redness or swelling.

Serious

• Development of inhibitors (antibodies) against factor VIII.
• Allergic reactions including anaphylaxis.
• Thromboembolic events.
• Renal dysfunction.

Clinicians should consider several precautions when prescribing Haemate P to ensure safe use.

• Assess inhibitor status before initiating therapy.
• Monitor for signs of allergic reactions during and after infusion.
• Use caution in patients with a history of thrombosis.
• Adjust dose in individuals with renal impairment.
• Avoid use in patients with known hypersensitivity to any component of the product.
• Ensure proper storage conditions to maintain product stability.

Haemate P may interact with other medications that affect coagulation or immune response.

Avoid

• Concomitant use of other factor VIII concentrates without medical supervision.
• Administration of pro‑thrombotic agents such as activated protein C.

Use with caution

• Antifibrinolytic agents (e.g., tranexamic acid) may increase clot stability.
• Immunosuppressive drugs that could alter inhibitor development.
• Certain antibiotics (e.g., beta‑lactams) that may provoke hypersensitivity.
• Vaccines administered shortly before or after infusion.